Table 3

Presumptive diagnostic categories assigned to reported SAE cases following Mectizan® treatment*

Diagnostic Category
Symptoms & Signs

Anaphylactic Reaction
Generalized immediate hypersensitivity response (urticaria, pruritis, angioedema, vascular collapse, life-threatening respiratory distress) after the administration of Mectizan®
Mild Mazzotti Reaction†
Manifestation of 2 or more of the following symptoms within 7 days of the administration of Mectizan®: pruritis, fever, headache, edema, lymphadenopathy, myalgia, generalized body aches
Severe Mazzotti Reaction†
Manifestation of 1 or both of the following symptoms within 7 days of the administration of Mectizan®: hypotension, asthma attacks in known patients; or manifestation of bullous skin lesions after 1–2 weeks of administration of Mectizan®
Functional Impairment with Normal Mental Status‡
Manifestation of symptoms typical of Mild Mazzotti Reaction at a severity such that patient required assistance with Activities of Daily Living (ADLs) (eating, bathing, walking) but maintained normal mental status within 7 days of the administration of Mecizan
Neurologic
Encephalopathy, meningitis, or other neurologic sequelae within 7 days of the administration of Mectizan®
Cardiovascular
Cardiovascular symptoms and signs, excluding hypotension, within 7 days of the administration of Mectizan®
Pulmonary
Respiratory symptoms and signs, excluding Mazzotti-type bronchoconstriction, within 7 days of the administration of Mectizan®
Gastrointestinal
Gastrointestinal symptoms including dehydration within 7 days of the administration of Mectizan®
Other
Any other symptoms and signs within 7 days of the administration of Mectizan®

*All cases met the definition of an SAE (See note 1) before being assigned one of these presumptive diagnoses; †adapted from McGavin DDM (1998). Opthalmology in the Tropics and Subtropics. In Manson's Tropical Diseases. 20th edn. (ed. GC Cook GC) W. B. Saunders Co. Ltd, London, p. 248; ‡adapted from Gardon J et al. [6].

Twum-Danso Filaria Journal 2003 2(Suppl 1):S3   doi:10.1186/1475-2883-2-S1-S3

Open Data